ftsv buy phase i/ii data aml nhl
recently-expand clinic pipelin remain
messag ftsv report result line expect investor
continu focu near-term phase ii data updat see preview
eha icml could potenti valid previously-observ
phase efficaci signal asset broader clinic develop program
featur recent expans clinic program within lymphoma link link remain
track compani guidanc reiter safeti efficaci updat ovarian
colorect cancer maintain buy pt
eye near-term clinic data readout eha icml line prior
guidanc see sf bu tour note ftsv present aml data relaps refractori
patient receiv monotherapi monotherapi safeti lead-in front-lin
aml/md patient treat azacitidin see preview encor
eha similarli updat non-hodgkin lymphoma data present eha
encor icml consist addit phase ii car-t inelig patient
treat mg/kg mg/kg dose addit follow-up initi patient
phase ib/ii portion manag emphas natur histori data
r/rdlbcl clinic bar beat demonstr orr cr rate
short durat month mo best support care ftsv note
eha abstract releas week contain initi data cut prior later cut time
present
preclinical-stag asset complet ind-en studi repres
potenti sourc long-term upsid beyond antibodi compani
develop anti-ckit antibodi condit regimen pre-bon marrow
transplant anti-sirpa antibodi oncolog indic
addit clinic data updat beyond readout ftsv reiter guidanc
report data phase ib trial evalu combin avelumab
cetuximab lly/mkkgi ovarian colorect cancer respect also
expect phase ib safeti efficaci result atezolizumab aml bladder
cancer
updat estim reflect result ftsv end quarter
cash invest compani expect fund oper
modestli increas expens forecast reflect result maintain buy
page analyst certif import disclosur
valuat risk
valu ftsv per share use dcf valuat valuat includ
lead product well probability-adjust cash flow deriv compani
 pipelin use discount rate consist commerci stage
biotech compani coverag termin growth rate risk
includ regulatori commerci setback potenti emerg new
competitor /or lower product sale expect risk intellectu properti
risk manag execut
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
